Pharmacovigilance: Monitoring and Reporting Adverse Drug Reactions
Journal Healthcare Treatment Development · 2022
DOI: 10.55529/jhtd.22.20.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal Healthcare Treatment Development, 2022. Verfasst von Shaik Fayaz Basha und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
Pharmacovigilance plays a pivotal role in ensuring the safety and efficacy of pharmaceutical products throughout their lifecycle. Monitoring and reporting adverse drug reactions (ADRs) are fundamental components of pharmacovigilance, aimed at identifying and minimizing risks associated with medication use. This paper provides an overview of the pharmacovigilance process, emphasizing the importance of robust ADR monitoring and reporting systems. It explores the various methods employed in pharmacovigilance, including spontaneous reporting, literature review, observational studies, and signal detection techniques. Additionally, the paper discusses the challenges and opportunities in ADR monitoring, such as underreporting, signal refinement, and the emergence of new data sources like social media and electronic health records. Strategies to enhance ADR reporting, including education and training initiatives for healthcare professionals and patients, as well as the utilization of advanced technology and data analytics, are also examined. Furthermore, the role of regulatory agencies, pharmaceutical companies, healthcare providers, and consumers in promoting pharmacovigilance efforts is highlighted.
Zitieren
APA
Basha, S. F., & Sanghavi, R. P. (2022). Pharmacovigilance: Monitoring and Reporting Adverse Drug Reactions. Journal Healthcare Treatment Development. https://doi.org/10.55529/jhtd.22.20.29
Vancouver
Basha SF, Sanghavi RP. Pharmacovigilance: Monitoring and Reporting Adverse Drug Reactions. Journal Healthcare Treatment Development. 2022. doi:10.55529/jhtd.22.20.29
BibTeX
@article{Basha2022,
author = {Basha, Shaik Fayaz and Sanghavi, R. P.},
title = {Pharmacovigilance: Monitoring and Reporting Adverse Drug Reactions},
journal = {Journal Healthcare Treatment Development},
year = {2022},
doi = {10.55529/jhtd.22.20.29}
}
EUVIMED